Freestone Capital Holdings, LLC Crispr Therapeutics Ag Transaction History

Freestone Capital Holdings, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 22, 2024	BUY	$60.67 - $89.12 $220,110 - $323,327	3,628 New	3,628 $247,000
Q4 2023 Feb 13, 2024	BUY	$38.62 - $72.18 $140,113 - $261,869	3,628 New	3,628 $227,000
Q2 2023 Aug 09, 2023	BUY	$43.47 - $67.77 $157,709 - $245,869	3,628 New	3,628 $203,000
Q1 2022 May 12, 2022	SELL	$53.19 - $79.24 $158,080 - $235,501	-2,972 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$70.09 - $111.29 $11,494 - $18,251	164 Added 5.84%	2,972 $225,000
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $5,069 - $7,205	-46 Reduced 1.61%	2,808 $314,000
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $287,797 - $462,034	2,854 New	2,854 $462,000
Q1 2021 May 17, 2021	SELL	$110.72 - $210.04 $48,606 - $92,207	-439 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$79.67 - $173.23 $26,291 - $57,165	330 Added 302.75%	439 $67.2 Million
Q3 2020 Nov 06, 2020	BUY	$78.5 - $100.64 $8,556 - $10,969	109 New	109 $9,000

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.23B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Freestone Capital Holdings, LLC, based on Form 13F filings with the SEC.

Stay updated on Freestone Capital Holdings, LLC with notifications on news.